Mitchell Chan
Director/Board Member bij AVALO THERAPEUTICS, INC.
Profiel
Mitchell Chan is an Independent Director at Avalo Therapeutics, Inc. and a Director at Maryland Technology Council.
He was previously a Director-Investor Relations at AstraZeneca PLC and the Chief Financial & Accounting Officer at Viela Bio, Inc. He holds an MBA from Rotman School of Management and undergraduate and graduate degrees from the University of Toronto.
Actieve functies van Mitchell Chan
Bedrijven | Functie | Begin |
---|---|---|
AVALO THERAPEUTICS, INC. | Director/Board Member | 01-12-2021 |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Director/Board Member | 11-03-2020 |
Eerdere bekende functies van Mitchell Chan
Bedrijven | Functie | Einde |
---|---|---|
VIELA BIO, INC. | Director of Finance/CFO | 15-03-2021 |
ASTRAZENECA PLC | Investor Relations Contact | - |
Opleiding van Mitchell Chan
Rotman School of Management | Masters Business Admin |
University of Toronto | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Commercial Services |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |